Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT05559801

PHASE1/PHASE2

Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

Sponsor: Emory University

View on ClinicalTrials.gov

Summary

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

Official title: A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

Key Details

Gender

All

Age Range

3 Years - 10 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-02

Completion Date

2026-10

Last Updated

2025-10-29

Healthy Volunteers

Conditions

Osteogenesis Imperfecta Osteogenesis Imperfecta Type III

Interventions

DRUG

Bone marrow-derived mesenchymal stromal cells (MSCs)

Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.

Inclusion Criteria: * 1\. Parent/legal guardian must be willing to sign consent forms to participate in this trial 2. Participants must be \>3 years of age and \<10 years of age at time of enrollment 3. Must carry mutation in either COL1A1 or COL1A2 genes and based on clinical assessment have severe Type 3 OI\* 4. Must be pre-pubertal to minimize potential influence of hormonal effects on growth velocity and BMD; for children who may be entering puberty at or near upper end of this age bracket, puberty assessment will be based on clinical and laboratory findings 5. Must have received IV pamidronate therapy for at least one year prior to study initiation. * Type 3 OI will be confirmed with an Invitae Skeletal Dysplasia test, and clinical assessment including: * Blue/grey sclerae * Presence of prenatal fractures (on ultrasound when available) * Deformities present at birth (confirming prenatal fractures) * Severity of fractures and progressive deformities although no absolute 'number' of fractures is available Exclusion Criteria: 1. Lacking confirmation of mutation in either COLA1A1 or COL1A2 genes 2. Other pathological types of OI 3. Any concurrent medical issue(s) known to decrease BMD (e.g., malabsorption conditions, glucocorticoid use) 4. Participation in other clinical trial 5. Vitamin D deficiency (\<20 ng/dL) despite treatment 6. Clinically significant thrombocytopenia as defined by a platelet count of \< 150,000x103/microliter ; anemia as defined by hemoglobin \< 5th percentile for age (\<11.5g/dL); neutropenia as defined by absolute neutrophil count \< 1.5 x103/microliter; or elevations in the white blood cell count as defined by 3-6 year old-WBC \> 15.5WBC x 103/microliter; 6-9 year old WBC \>13.5 x103/microliter (Flerlage 2015) 8\. PRA screening positive for anti-HLA antibodies 9. Elevated LFT's greater than 2 times the upper limit of normal 10. Other genetic disorders 11. Other skeletal dysplasia disorders 12. Other primary or secondary bone disorders 13. History of acute or chronic infections 14. History of cancer 15. History of thrombosis or prothrombotic disorders 16. History of heart disease 17. History of diabetes 18. History of strokes 19. History of vascular conditions 20. History of lung disease